Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, including the makers of Xarelto, possess a duty to ensure that their drugs are reasonably protected for use - and failure to perform so could be grounds for compensation. Our lawyers are working tough to have those hurt by the drug the compensation they may be entitled to.
Even though bleeding can be a common complication linked with anticoagulants, it has been alleged that Xarelto is more unsafe than conventional blood thinners simply because no antidote exists to reverse its blood-thinning effects. This signifies that, within the event of an emergency, patients may be at threat for irreversible bleeding difficulties, which includes life-threatening internal and gastrointestinal hemorrhaging.
If you or even a loved a single suffered a critical bleeding event following taking Xarelto, you may have legal recourse. For far more data, contact us today to have your case reviewed, free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for past and future medical bills, lost wages, discomfort and suffering and, in instances of death, funeral expenditures. In addition, they're seeking punitive damages, that are generally awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is dangerous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Simply because of this, the lawsuits claim, doctors have no effective indicates of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs inside the lawsuits allege critical and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user inside the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of
governance.org.ua suffering a fatal bleeding occasion.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of
effectiveness in preventing harmful clotting.
Visit this page for much more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.